Strategies for the prevention and treatment of osteoporosis during early postmenopause

American Journal of Obstetrics and Gynecology

Volumn 194, Issue 2 SUPPL., 2006, Pages

  Delaney, Miriam F ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Early postmenopause; Fracture; Osteoporosis; Prevention; Treatment

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; GESTAGEN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

ABDOMINAL PAIN; ALCOHOL CONSUMPTION; BONE DENSITY; BONE MASS; CALCIUM INTAKE; CLINICAL PRACTICE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; EARLY INTERVENTION; EXERCISE; FALLING; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HEADACHE; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPERCALCEMIA; LEG CRAMP; LIFESTYLE; NAUSEA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RHINITIS; RISK ASSESSMENT; SMOKING CESSATION; TABLET; TREATMENT PLANNING; VITAMIN INTAKE;

ACCIDENTAL FALLS; AGED; ALENDRONATE; BONE DENSITY; CALCITONIN; CALCIUM, DIETARY; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; ETIDRONIC ACID; EXERCISE; FEMALE; HUMANS; LIFE STYLE; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PERIMENOPAUSE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SMOKING; VITAMIN D;

EID: 31444447411     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2005.08.049     Document Type: Review

References (106)

1. National Osteoporosis Foundation Physician's guide to prevention and treatment of osteoporosis 2003 National Osteoporosis Foundation Washington (DC) p. 1-37
2. North American Menopause Society Management of postmenopausal osteoporosis: position statement of the North American Menopause Society Menopause 9 2002 84 101
3. J.P. Brown, and R.G. Josse 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. For the Scientific Advisory Council of the Osteoporosis Society of Canada CMAJ 167 Suppl 10 2002 S1 S34
4. US Preventive Services Task Force Screening for osteoporosis in postmenopausal women: recommendations and rationale Ann Intern Med 137 2002 526 528
5. R. Eastell Pathogenesis of postmenopausal osteoporosis M.J. Favus Primer on the metabolic bone diseases and disorders of mineral metabolism 5th ed. 2003 American Society for Bone and Mineral Research Washington (DC) 314 316
6. R. Recker, J. Lappe, K. Davies, and R. Heaney Characterization of perimenopausal bone loss: a prospective study J Bone Miner Res 15 2000 1965 1973
7. B. Abrahamsen, N. Nissen, A.P. Hermann, B. Hansen, O. Bärenholdt, and P. Vestergaard When should densitometry be repeated in healthy peri- and postmenopausal women?: the Danish Osteoporosis Prevention Study J Bone Miner Res 17 2002 2061 2067
8. D. Marshall, O. Johnell, and H. Wedel Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures BMJ 312 1996 1254 1259
9. D. Picard, A. Imbach, M. Couturier, R. Lepage, and L.-G. Ste Marie Longitudinal study of bone density and its determinants in women in peri- or early menopause Calcif Tissue Int 67 2000 356 360
10. P. Ravn, G. Cizza, N.H. Bjarnason, D. Thompson, M. Daley, and R.D. Wasnich Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group J Bone Miner Res 14 1999 1622 1627
11. H.K. Genant, C. Cooper, G. Poor, I. Reid, G. Ehrlich, and J. Kanis Interim report and recommendations of the World Health Organization task-force for osteoporosis Osteoporos Int 10 1999 259 264
12. S.E. Andrade, S.R. Majumdar, K.A. Chan, D.S. Buist, A.S. Go, and M. Goodman Low frequency of treatment of osteoporosis among postmenopausal women following a fracture Arch Intern Med 163 2003 2052 2057
13. M.J.M. Panneman, P. Lips, S.S. Sen, and R.M.C. Herings Undertreatment with anti-osteoporotic drugs after hospitalization for fracture Osteoporos Int 15 2004 120 124
14. K.B. Freedman, F.S. Kaplan, W.B. Bilker, B.L. Strom, and R.A. Lowe Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am 82 A 2000 1063 1070
15. C. Simonelli, K. Killeen, S. Mehle, and L. Swanson Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons Mayo Clin Proc 77 2002 334 338
16. American College of Obstetricians and Gynecologists Clinical management guidelines for obstetrician-gynecologists, ACOG practice bulletin 50 Obstet Gynecol 103 2004 203 216
17. AACE Guidelines American Association of Clinical Endocrinologists (AACE) medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003 Endocr Pract 9 2003 544 564
18. World Health Organization Study Group Assessment of fracture risk and its application to screening for postmenopausal osteoporosis World Health Organ Tech Rep Ser 843 1994 1 129
19. R. Lindsay, and F. Cosman Osteoporosis E. Braunwald A.S. Fauci D.L. Kasper S.L. Hauser D.L. Longo J.L. Jameson Harrison's Principles of Internal Medicine 15th ed. 2001 McGraw-Hill New York 2226 2237
20. B. Dawson-Hughes Vitamin D and calcium: recommended intake for bone health Osteoporos Int 8 Suppl 2 1998 S30 S34
21. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes Food and Nutrition Board Institute of Medicine Calcium and related nutrients: overview and methods Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride 2003 National Academy Press Washington (DC) 38 53
22. J.E. South-Paul Osteoporosis: part II, nonpharmacologic and pharmacologic treatment Am Fam Physician 63 2001 1121 1128
23. M. Sinaki Nonpharmacologic interventions: exercise, fall prevention, and role of physical medicine Clin Geriatr Med 19 2003 337 359
24. T. Lloyd, T.J. Beck, H.-M. Lin, M. Tulchinsky, D.F. Eggli, and T.L. Oreskovic Modifiable determinants of bone status in young women Bone 30 2002 416 421
25. E. Ernst Exercise for female osteoporosis: a systematic review of randomised clinical trials Sports Med 25 1998 359 368
26. D. Feskanich, W. Willett, and G. Colditz Walking and leisure-time activity and risk of hip fracture in postmenopausal women JAMA 288 2002 2300 2306
27. W. Kemmler, K. Engelke, D. Lauber, J. Weineck, J. Hensen, and W.A. Kalender Exercise effects on fitness and bone mineral density in early postmenopausal women: 1-year EFOPS results Med Sci Sports Exerc 34 2002 2115 2123
28. W. Kemmler, D. Lauber, J. Weineck, J. Hensen, W. Kalender, and K. Engelke Benefits of 2 years of intense exercise on bone density, physical fitness, and blood lipids in early postmenopausal osteopenic women: results of the Erlangen Fitness Osteoporosis Prevention Study (EFOPS) Arch Intern Med 164 2004 1084 1091
29. S. Going, T. Lohman, L. Houtkooper, L. Metcalfe, H. Flint-Wagner, and R. Blew Effects of exercise on bone mineral density in calcium-replete postmenopausal women with and without hormone replacement therapy Osteoporos Int 14 2003 637 643
30. M. Pfeifer, B. Begerow, H.W. Minne, T. Schlotthauer, M. Pospeschill, and M. Scholz Vitamin D status, trunk muscle strength, body sway, falls, and fractures among 237 postmenopausal women with osteoporosis Exp Clin Endocrinol Diabetes 109 2001 87 92
31. H.A. Bischoff, H.B. Stahelin, W. Dick, R. Akos, M. Knecht, and C. Salis Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial J Bone Miner Res 18 2003 343 351
32. S. O'Neill, P. Sambrook, T. Diamond, P. Ebeling, L. Ferris, and L. Flicker Guidelines for the treatment of postmenopausal osteoporosis for general practitioners Aust Fam Physician 31 2002 1 8
33. D.M. Black, S.R. Cummings, D.B. Karpf, J.A. Cauley, D.E. Thompson, and M.C. Nevitt Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1996 1535 1541
34. S.R. Cummings, D.M. Black, D.E. Thompson, W.B. Applegate, E. Barrett-Connor, and T.A. Musliner Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 1998 2077 2082
35. B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, and H.K. Genant Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 1999 637 645
36. S.T. Harris, N.B. Watts, H.K. Genant, C.D. McKeever, T. Hangartner, and M. Keller Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 1999 1344 1352
37. C.H. Chesnut 3rd, S. Silverman, K. Andriano, H. Genant, A. Gimona, and S. Harris A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group Am J Med 109 2000 267 276
38. M.R. McClung, P. Geusens, P.D. Miller, H. Zippel, W.G. Bensen, and C. Roux Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 2001 333 340
39. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, and J.-Y. Reginster Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 2001 1434 1441
40. J.Y. Reginster, H.W. Minne, O.H. Sorensen, M. Hooper, C. Roux, and M.L. Brandi Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 2000 83 91
41. T.-S. Yang, S.-H. Tsan, C.-R. Chen, S.-P. Chang, and C.-C. Yuan Effects of alendronate on bone turnover markers in early postmenopausal women Chin Med J (Taipei) 61 1998 568 576
42. D. Hosking, C.E.D. Chilvers, C. Christiansen, P. Ravn, R. Wasnich, and P. Ross Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group N Engl J Med 338 1998 485 492
43. L. Mortensen, P. Charles, P.J. Bekker, J. Digennaro, and C.C. Johnston Jr. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up J Clin Endocrinol Metab 83 1998 396 402
44. P. Ravn, S.R. Weiss, J.A. Rodriguez-Portales, M.R. McClung, R.D. Wasnich, and N.L. Gilchrist Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group J Clin Endocrinol Metab 85 2000 1492 1497
45. E.E. Jolly, N.H. Bjarnason, P. Neven, L. Plouffe Jr., C.C. Johnston Jr., and S.D. Watts Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years Menopause 10 2003 337 344
46. S.J.M. Neele, R. Evertz, G.D. Valk-De Roo, J.C. Roos, and J.C. Netelenbos Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women Bone 30 2002 599 603
47. S.C. Manolagas Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis Endocr Rev 21 2000 115 137
48. D.G. Monroe, and T.C. Spelsberg Gonadal steroids and receptors M.J. Favus Primer on the metabolic bone diseases and disorders of mineral metabolism 5th ed. 2003 American Society for Bone and Mineral Research Washington (DC) 32 38
49. H.K. Genant, J. Lucas, S. Weiss, M. Akin, R. Emkey, and H. McNaney-Flint Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group Arch Intern Med 157 1997 2609 2615
50. R. Lindsay, F. Cosman, R.A. Lobo, B.W. Walsh, S.T. Harris, and J.E. Reagan Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial J Clin Endocrinol Metab 84 1999 3076 3081
51. J.A. Cauley, J. Robbins, Z. Chen, S.R. Cummings, R.D. Jackson, and A.Z. Lacroix Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial JAMA 290 2003 1729 1738
52. The Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
53. R. Lindsay, J.C. Gallagher, M. Kleerekoper, and J.H. Pickar Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women JAMA 287 2002 2668 2676
54. C.J. Rosen, C.H. Chesnut 3rd, and N.J.S. Mallinak The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation J Clin Endocrinol Metab 82 1997 1904 1910
55. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. Lacroix, C. Kooperberg, and M.L. Stefanick Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Writing Group for the Women's Health Initiative Investigators JAMA 288 2002 321 333
56. FDA updates hormone therapy information for post menopausal women [press release]. US Food and Drug Administration: FDA News; February 10, 2004.
57. A.L. Hersh, M.L. Stefanick, and R.S. Stafford National use of postmenopausal hormone therapy: annual trends and response to recent evidence JAMA 291 2004 47 53
58. B. Ettinger, D. Grady, A.N.A. Tosteson, A. Pressman, and J.L. Macer Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy Obstet Gynecol 102 2003 1225 1232
59. S.L. Greenspan, R.D. Emkey, H.G. Bone 3rd, S.R. Weiss, N.H. Bell, and R.W. Downs Jr. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: a randomized, double-blind, placebo-controlled trial Ann Intern Med 137 2002 875 883
60. J.C. Gallagher, P.B. Rapuri, G. Haynatzki, and J.R. Detter Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers J Clin Endocrinol Metab 87 2002 4914 4923
61. J. Yates, E. Barrett-Connor, S. Barlas, Y.-T. Chen, P.D. Miller, and E.S. Siris Rapid loss of hip fracture protection after estrogen cessation: evidence from the national osteoporosis risk assessment Obstet Gynecol 103 2004 440 446
62. E. Barrett-Connor, L.E. Wehren, E.S. Siris, P. Miller, Y.-T. Chen, and T.A. Abbott 3rd Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study Menopause 10 2003 412 419
63. A.A. Reszka, and G.A. Rodan Bisphosphonate mechanism of action Curr Rheumatol Rep 5 2003 65 74
64. P.J. Meunier, M. Arlot, P. Chavassieux, and A.J. Yates The effects of alendronate on bone turnover and bone quality Int J Clin Pract 101 suppl 1999 14 17
65. H.G. Bone, D. Hosking, J.-P. Devogelaer, J.R. Tucci, R.D. Emkey, and R.P. Tonino Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 2004 1189 1199
66. M.M. Luckey, N. Gilchrist, H.G. Bone, M.W. Davie, T.J. de Villiers, and M. Wu Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis Obstet Gynecol 101 2003 711 721
67. J.T. Harrington, L.-G. Ste-Marie, M.L. Brandi, R. Civitelli, P. Fardellone, and A. Grauer Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis Calcif Tissue Int 74 2004 129 135
68. C. Roux, E. Seeman, R. Eastell, J. Adachi, R.D. Jackson, and D. Felsenberg Efficacy of risedronate on clinical vertebral fractures within six months Curr Med Res Opin 20 2004 433 439
69. R.P. Heaney, T.M. Zizic, I. Fogelman, W.P. Olszynski, P. Geusens, and C. Kasibhatla Risedronate reduces the risk of first vertebral fracture in osteoporotic women Osteoporos Int 13 2002 501 505
70. O.H. Sorensen, G.M. Crawford, H. Mulder, D.J. Hosking, C. Gennari, and D. Mellstrom Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience Bone 32 2003 120 126
71. O. Sorensen, S. Goemare, D. Wenderoth, A. Chines, and C. Roux Sustained effect of risedronate: a 7-year study in postmenopausal women [abstract P-275] Calcif Tissue 72 2003 402
72. R. Lindsay, S.L. Silverman, C. Cooper, D.A. Hanley, I. Barton, and S.B. Broy Risk of new vertebral fracture in the year following a fracture JAMA 285 2001 320 323
73. P.D. Delmas, R. Balena, E. Confravreux, C. Hardouin, P. Hardy, and A. Bremond Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study J Clin Oncol 15 1997 955 962
74. J.P. Brown, D.L. Kendler, M.R. McClung, R.D. Emkey, J.D. Adachi, and M.A. Bolognese The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis Calcif Tissue Int 71 2002 103 111
75. S.T. Harris, N.B. Watts, Z. Li, A.A. Chines, D.A. Hanley, and J.P. Brown Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis Curr Med Res Opin 20 2004 757 764
76. T.E. Dufresne, P.A. Chmielewski, M.D. Manhart, T.D. Johnson, and B. Borah Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography Calcif Tissue Int 73 2003 423 432
77. R. Lindsay, J.D. Adachi, I.P. Barton, and M.D. Manhart Fracture risk reduction due to antiresorptive treatment is independent of the magnitude of BMD improvement Arthritis Rheum 48 2003 S84
78. US Food and Drug Administration and Center for Drug Evaluation and Research Web site. http://www.accessdata/fda/gov/scripts/ceder/drugsatfda/index. cfm?fuseaction=Search.Overview&DrugName=BONIVA. Accessed November 12, 2004.
79. C.H. Chesnut 3rd, A. Skag, C. Christiansen, R. Recker, J.A. Stakkestad, and A. Hoiseth Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 2004 1241 1249
80. M.R. McClung, R.D. Wasnich, R. Recker, J.A. Cauley, C.H. Chesnut 3rd, and K.E. Ensrud Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis J Bone Miner Res 19 2004 11 18
81. L.B. Tankó, D. Felsenberg, E. Czerwiński, A. Burdeska, I. Jonkanski, and C. Hughes Oral weekly ibandronate prevents bone loss in postmenopausal women J Intern Med 254 2003 159 167
82. A.B.R. Thomson, J.K. Marshall, R.H. Hunt, J.M. Provenza, F.L. Lanza, and M.G. Royer 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status J Rheumatol 29 2002 1965 1974
83. K. Worley, J.J. Doyle, A. Klemes, R.L. Sheer, and M. Steinbuch Incidence of gastrointestinal events among patients treated with alendronate versus risedronate Endocrine Pract 9 Suppl 1 2003 11 12
84. Borisov NN, Doyle J, Brezovic CP, Sheer RL. Economic evaluation of the relationship between gastrointestinal events and bisphosphonate therapy: risedronate versus alendronate. Poster presented at: American Association of Clinical Endocrinologists' (AACE) 12th Annual Meeting and Clinical Congress; May 14, 2003; San Diego, CA.
85. N. Watts, D. Freedholm, and A. Daifotis The clinical tolerability profile of alendronate Int J Clin Pract 101 Suppl 1999 51 61
86. J.J. Body Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis Bone 30 2002 75S 79S
87. I. MacIntyre, J.C. Stevenson, M.I. Whitehead, S.J. Wimalawansa, L.M. Banks, and M.J.R. Healy Calcitonin for prevention of postmenopausal bone loss Lancet 1 1988 900 902
88. M. Meschia, M. Brincat, P. Barbacini, P.G. Crossignani, and W. Albisetti A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women Calcif Tissue Int 53 1993 17 20
89. Miacalcin [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corp; 2003.
90. W. Khovidhunkit, and D.M. Shoback Clinical effects of raloxifene hydrochloride in women Ann Intern Med 130 1999 431 439
91. S.M. Ott, A. Oleksik, Y. Lu, K. Harper, and P. Lips Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women J Bone Miner Res 17 2002 341 348
92. K.M. Prestwood, M. Gunness, D.B. Muchmore, Y. Lu, M. Wong, and L.G. Raisz A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women J Clin Endocrinol Metab 85 2000 2197 2202
93. E.G. Lufkin, M.D. Whitaker, T. Nickelsen, R. Argueta, R.H. Caplan, and R.K. Knickerbocker Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial J Bone Miner Res 13 1998 1747 1754
94. P.D. Delmas, K.E. Ensrud, J.D. Adachi, K.D. Harper, S. Sarkar, and C. Gennari Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial J Clin Endocrinol Metab 87 2002 3609 3617
95. M. Maricic, J.D. Adachi, S. Sarkar, W. Wu, M. Wong, and K.D. Harper Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis Arch Intern Med 162 2002 1140 1143
96. Q. Rehman, T.F. Lang, C.D. Arnaud, G.W. Modin, and N.E. Lane Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis Osteoporos Int 14 2003 77 81
97. N.E. Lane, and A. Kelman A review of anabolic therapies for osteoporosis Arthritis Res Ther 5 2003 214 222
98. Forteo [package insert]. Indianapolis: Eli Lilly and Company; 2002.
99. D.M. Black, S.L. Greenspan, K.E. Ensrud, L. Palermo, J.A. McGowan, and T.F. Lang The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N Engl J Med 349 2003 1207 1215
100. S.T. Harris, E.F. Eriksen, M. Davidson, M.P. Ettinger, A.H. Moffett Jr., and D.J. Baylink Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women J Clin Endocrinol Metab 86 2001 1890 1897
101. J.S. Finkelstein, A. Hayes, J.L. Hunzelman, J.J. Wyland, H. Lee, and R.M. Neer The effects of parathyroid hormone, alendronate, or both in men with osteoporosis N Engl J Med 349 2003 1216 1226
102. B. Ettinger, J. San Martin, G. Crans, and I. Pavo Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate J Bone Miner Res 19 2004 745 751
103. O. Johnell, W.H. Scheele, Y. Lu, J.-Y. Reginster, A.G. Need, and E. Seeman Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis J Clin Endocrinol Metab 87 2002 985 992
104. Fosamax [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2003.
105. Physicians' Desk Reference electronic library. Evista (raloxifene hydrochloride) tablets. PDR; 2001.
106. Actonel [package insert]. Kansas City (MO): Aventis Pharmaceuticals Inc; 2003.